Infectious titer determination of lentiviral vectors using a temporal immunological real-time imaging approach.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 25 04 2021
accepted: 01 07 2021
entrez: 15 7 2021
pubmed: 16 7 2021
medline: 12 11 2021
Statut: epublish

Résumé

The analysis of the infectious titer of the lentiviral vector samples obtained during upstream and downstream processing is of major importance, however, also the most challenging method to be performed. Currently established methods like flow cytometry or qPCR lack the capability of enabling high throughput sample processing while they require a lot of manual handling. To address this limitation, we developed an immunological real-time imaging method to quantify the infectious titer of anti-CD19 CAR lentiviral vectors with a temporal readout using the Incucyte® S3 live-cell analysis system. The infective titers determined with the Incucyte® approach when compared with the flow cytometry-based assay had a lower standard deviation between replicates and a broader linear range. A major advantage of the method is the ability to obtain titer results in real-time, enabling an optimal readout time. The presented protocol significantly decreased labor and increased throughput. The ability of the assay to process high numbers of lentiviral samples in a high throughput manner was proven by performing a virus stability study, demonstrating the effects of temperature, salt, and shear stress on LV infectivity.

Identifiants

pubmed: 34265014
doi: 10.1371/journal.pone.0254739
pii: PONE-D-21-13702
pmc: PMC8281989
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0254739

Déclaration de conflit d'intérêts

The authors declare no competing financial, professional, or personal interests that may have influenced the work described in this manuscript. The commercial affiliation reported in the financial disclosure statement did not give rise to any type of competing interest. The commercial affiliation does not alter our adherence to PLOS ONE policies on sharing data and materials.

Références

J Biomol Screen. 1999;4(2):67-73
pubmed: 10838414
J Virol Methods. 2015 Jun 15;218:59-65
pubmed: 25796989
Mol Cells. 2017 May 31;40(5):339-345
pubmed: 28535668
Mol Ther Methods Clin Dev. 2020 Mar 30;17:717-730
pubmed: 32346549
BMC Biotechnol. 2006 Jul 12;6:34
pubmed: 16836756
Biotechnol Adv. 2006 May-Jun;24(3):321-37
pubmed: 16448798
Methods Mol Biol. 2020;2086:69-76
pubmed: 31707668
Hum Gene Ther. 2003 Apr 10;14(6):497-507
pubmed: 12718761
Gene Ther. 2021 Feb;28(1-2):89-104
pubmed: 32973351
J Gen Virol. 2015 Dec;96(12):3507-3518
pubmed: 26432090
J Gene Med. 2009 Aug;11(8):670-8
pubmed: 19507176
Viruses. 2021 Feb 09;13(2):
pubmed: 33572347
PLoS Pathog. 2015 Aug 28;11(8):e1005091
pubmed: 26317997
Sci Rep. 2015 Sep 08;5:13875
pubmed: 26348152
J Hematol Oncol. 2019 Jun 20;12(1):62
pubmed: 31221182
J Transl Med. 2016 Oct 12;14(1):288
pubmed: 27729044
Curr Gene Ther. 2005 Aug;5(4):387-98
pubmed: 16101513
Biotechnol Bioeng. 2005 May 20;90(4):391-404
pubmed: 15812800
Virology. 2001 Feb 1;280(1):124-31
pubmed: 11162826
Gene Ther. 2005 Oct;12 Suppl 1:S36-50
pubmed: 16231054
Hematol Transfus Cell Ther. 2020 Apr - Jun;42(2):150-158
pubmed: 31676276
Curr Biol. 2018 Oct 22;28(20):3212-3219.e4
pubmed: 30318351
Methods Mol Biol. 2019;1879:347-365
pubmed: 30006865
J Gen Virol. 2014 Dec;95(Pt 12):2649-2657
pubmed: 25096816
Mol Ther Methods Clin Dev. 2019 Aug 30;15:52-62
pubmed: 31649955
J Biotechnol. 2021 Jan 20;326:11-20
pubmed: 33301854
Virology. 2003 Mar 30;308(1):137-46
pubmed: 12706097
Biotechnol J. 2021 Jan;16(1):e2000019
pubmed: 33089626
Mol Biotechnol. 2015 Feb;57(2):195-200
pubmed: 25370825
J Mark Access Health Policy. 2016 Apr 25;4:
pubmed: 27123193
Drug Discov Today. 2018 Jun;23(6):1175-1182
pubmed: 29501911
Am J Cancer Res. 2019 Feb 01;9(2):228-241
pubmed: 30906625
Curr Pharm Biotechnol. 2018;19(1):5-18
pubmed: 29667553
J Virol Methods. 2014 Dec;209:35-40
pubmed: 25194890
Viruses. 2014 Feb 13;6(2):782-807
pubmed: 24531335
Int J Mol Sci. 2019 Jan 29;20(3):
pubmed: 30700020
BMC Biotechnol. 2011 May 20;11:55
pubmed: 21599966
Nat Protoc. 2009;4(4):495-505
pubmed: 19300443
PLoS One. 2015 Apr 20;10(4):e0124708
pubmed: 25894652
BMC Biotechnol. 2009 Feb 16;9:10
pubmed: 19220915

Auteurs

Jennifer J Labisch (JJ)

Lab Essentials Applications Development, Sartorius Stedim Biotech GmbH, Göttingen, Lower Saxony, Germany.
Institute of Technical Chemistry, Leibniz University Hannover, Hannover, Lower Saxony, Germany.

G Philip Wiese (GP)

Lab Essentials Applications Development, Sartorius Stedim Biotech GmbH, Göttingen, Lower Saxony, Germany.
Faculty of Mathematics, Computer Science and Natural Sciences, RWTH Aachen University, Aachen, North Rhine-Westphalia, Germany.

Kalpana Barnes (K)

BioAnalytics Applications, Essen BioScience, Royston, Hertfordshire, United Kingdom.

Franziska Bollmann (F)

Segment Marketing Viral-based Therapeutics, Sartorius Stedim Biotech GmbH, Göttingen, Lower Saxony, Germany.

Karl Pflanz (K)

Lab Essentials Applications Development, Sartorius Stedim Biotech GmbH, Göttingen, Lower Saxony, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH